Neuren Pharmaceuticals (FRA:NK9) General and Admin. Expense: €3.52 Mil (TTM As of Dec. 2025)


FRA:NK9 Neuren Pharmaceuticals Ltd FRA:NK9
54 GF Score
Price €9.85
GF Value €4.22
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals General and Admin. Expense?

Neuren Pharmaceuticals FRA:NK9 -0.51% 54 General and Admin. Expense is €3.52 Mil as of Dec. 2025. GuruFocus rates FRA:NK9 with a GF Score™ of 54/100 and a GF Value™ of €4.22 (Significantly Overvalued). The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Neuren Pharmaceuticals's General and Admin. Expense for the six months ended in Dec. 2025 was €2.12 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €3.52 Mil.

Neuren Pharmaceuticals General and Admin. Expense Related Terms

Neuren Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals General and Admin. Expense Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 2.19 3.65 2.84 3.53

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.46 1.41 1.40 2.12
FRA:NK9
54GF Score
Neuren Pharmaceuticals Ltd FRA:NK9
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €3.52 Mil mean?
Neuren Pharmaceuticals (FRA:NK9) has a General and Admin. Expense of €3.52 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' General and Admin. Expense too high?
Neuren Pharmaceuticals' current General and Admin. Expense is €3.52 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' General and Admin. Expense compare to VRTX and REGN?
Neuren Pharmaceuticals' General and Admin. Expense of €3.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current General and Admin. Expense is €3.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (FRA:NK9) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.22, compared to a current price of €9.85 — trading 133.4% above its estimated fair value. The current General and Admin. Expense is €3.52 Mil. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Neuren Pharmaceuticals (FRA:NK9), the current General and Admin. Expense is €3.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (FRA:NK9) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of €9.85 is trading 133.4% above its estimated GF Value™ of €4.22. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:NK9:

  • General and Admin. Expense: €3.52 Mil
  • GF Value™: €4.22 vs. price of €9.85 (133.4% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FRA:NK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score

Get the complete analysis for FRA:NK9

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.85
Price
€4.22
GF Value